Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2397-768X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer ; volume:6 ; number:1 ; day:24 ; month:9 ; year:2022 ; pages:1-16 ; date:12.2022
npj precision oncology ; 6, Heft 1 (24.9.2022), 1-16, 12.2022
- Urheber
-
Al-Qasem, Abeer J.
Alves, Carla L.
Ehmsen, Sidse
Tuttolomondo, Martina
Terp, Mikkel G.
Johansen, Lene E.
Vever, Henriette
Hoeg, Luna V. A.
Elias, Daniel
Bak, Martin
Ditzel, Henrik J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-022-00311-6
- URN
-
urn:nbn:de:101:1-2022121221032281338988
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Al-Qasem, Abeer J.
- Alves, Carla L.
- Ehmsen, Sidse
- Tuttolomondo, Martina
- Terp, Mikkel G.
- Johansen, Lene E.
- Vever, Henriette
- Hoeg, Luna V. A.
- Elias, Daniel
- Bak, Martin
- Ditzel, Henrik J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Regulation of CDK4
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
The role of targeting CDK4/6 in cancer immunotherapy
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
CDK4, pRB and E2F1: connected to insulin
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elevated expression of CDK4 in lung cancer
CDK4/6 inhibition in luminal breast cancer
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Regulation of CDK4
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
The role of targeting CDK4/6 in cancer immunotherapy
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
CDK4, pRB and E2F1: connected to insulin
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elevated expression of CDK4 in lung cancer
CDK4/6 inhibition in luminal breast cancer
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Regulation of CDK4
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
The role of targeting CDK4/6 in cancer immunotherapy
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
CDK4, pRB and E2F1: connected to insulin
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Elevated expression of CDK4 in lung cancer
CDK4/6 inhibition in luminal breast cancer
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma